Belite Bio, Inc, recently announced positive secondary endpoint data from its phase 3 DRAGON trial of oral tinlarebant (LBS-008) for the treatment of Stargardt disease type 1 (STGD1).
These findings, in addition to previously reported topline data, were presented during the American Society of Retina Specialists (ASRS) 2026 annual meeting in Montréal, Canada, earlier this month.
Let’s start with a refresher on tinlarebant.
Belite Bio’s lead asset is a once-daily orally-administered tablet under clinical investigation for early intervention in maintaining retinal tissue healthy among patients with STGD1 and geographic atrophy (GA).
Its mechanism: Lowering levels of retinol binding protein 4 (RBP4), which is the sole carrier protein for retinol (Vitamin A) transport from the liver to the eye.
The intended effect: To reduce the accumulation of retinol, thereby decreasing the formation of bisretinoids (which are toxic by-products) within the eye that cause STGD1 and contribute to GA.
Has tinlarebant received any FDA designations?
Yes: four FDA designations for its STGD1 indication, including:
- Breakthrough Therapy
- Fast Track
- Rare Pediatric Disease
- Orphan Drug
Note: Breakthrough Therapy designation also grants the company priority review eligibility for tinlarebant’s regulatory submission as well as more frequent meetings with the federal agency (which we’ll revisit shortly).
And wasn’t Belite Bio just in the news?
Indeed. The company announced last month that it had completed rolling submission of its new drug application (NDA) to the FDA for tinlarebant in STGD1.
- Note: We are now more than halfway into the ensuing 60-day review period for the FDA to accept or reject the submission.
Pending positive results: With its multiple designations, the review period leading up to the Prescription Drug User Fee Act (PDUFA) may only be 6 months instead of the standard 10-month duration.
To take it one step further: Tinlarebant has the potential to be the first FDA-approved therapeutic intervention for the treatment of STGD1.
With that out of the way, how has it performed in previous clinical trials?
Favorably—and promising, based on what we’ve seen from both phase 1 and 2 studies.
Specifically, tinlarebant has been found to:
- Stabilize visual acuity (VA), especially among patients with severe vision loss
- Halt atrophic lesion growth within the macula among 75% of patients by year 2 of treatment
Let’s move on to the phase 3 trial.
The DRAGON study (NCT05244304) was a 24-month, randomized, double-masked, placebo-controlled phase 3 clinical trial of orally administered tinlarebant (5 mg/day) in 104 patients (aged 12 to 20) with STGD1.
The primary endpoint: reduction in definitively decreased autofluorescence (DDAF) lesion growth rate, assessed via fundus autofluorescence (FAF).
Starting with the efficacy data…
Administration of tinlarebant decreased RBP4 levels by 80%, and met its primary goal of a statistically significant 35.7% slowing of DDAF lesion growth—as compared to placebo at 25 months (P=0.0033).
Moreover: Quantitative autofluorescence (qAF), a marker of toxic bisretinoid accumulation, showed a marked divergence between treatment groups at Month 25:
- Tinlarebent-treated patients remained stable to slightly decreased from baseline (approximately 2%)
- Placebo-treated patients demonstrated an approximate 20% increase from baseline
And the safety findings?
Tinlarebent was well tolerated, as ocular and non-ocular treatment-emergent adverse events (TEAEs) were mostly mild, and no serious ocular TEAEs were reported.
Plus: Best-corrected visual acuity (BCVA) remained stable in both groups.
- Get a full rundown of the topline findings from the phase 3 DRAGON trial here.
Before we close, are there any updates on tinlarebent for GA?
The phase 3 PHOENIX trial (NCT05949593) evaluating tinlarebent for GA has completed enrollment and is currently underway. Its estimated primary completion date: June 30, 2027.
Stay tuned for updates regarding the FDA’s decision on the NDA!